For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and Tafamidis meglumine represents a true advancement . These innovative therapies protect the transthyretin protein, slowing its destructive build-up and reducing the impact of the disease . Individuals are now experienci